Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma
Abstract A subgroup analysis of a randomized study demonstrated that patients with advanced or metastatic liposarcoma treated with eribulin had longer overall survival and progression-free survival compared to those treated with dacarbazine, suggesting eribulin as a therapeutic option for advanced l...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-84247-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594826994909184 |
|---|---|
| author | Miaomiao Zhang Jinlong Huang Xiaochun Zheng Ping Huang Xiuli Yang |
| author_facet | Miaomiao Zhang Jinlong Huang Xiaochun Zheng Ping Huang Xiuli Yang |
| author_sort | Miaomiao Zhang |
| collection | DOAJ |
| description | Abstract A subgroup analysis of a randomized study demonstrated that patients with advanced or metastatic liposarcoma treated with eribulin had longer overall survival and progression-free survival compared to those treated with dacarbazine, suggesting eribulin as a therapeutic option for advanced liposarcoma. Therefore, this study aims to evaluate the cost-effectiveness of eribulin versus dacarbazine in the treatment of advanced liposarcoma. We established a 10-year Markov model to compare the cost-effectiveness of eribulin and dacarbazine regimens. Clinical data were sourced from a subgroup analysis of a multicenter, randomized, open-label phase 3 trials. Quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were computed. The total cost of the dacarbazine scheme was $10,895.558, with a QALY of 0.533. In contrast, the total cost of the eribulin scheme was $16,961.891, with a QALY of 0.698. The ICER between the eribulin and dacarbazine schemes was $36,736.467, which is below the willingness-to-pay (WTP) threshold in China ($37,877.469). From the perspective of the Chinese healthcare system, eribulin is cost-effective compared to dacarbazine at the WTP threshold. |
| format | Article |
| id | doaj-art-4de9883cd811462bb3725b586c11788e |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-4de9883cd811462bb3725b586c11788e2025-01-19T12:17:04ZengNature PortfolioScientific Reports2045-23222025-01-0115111010.1038/s41598-024-84247-wCost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcomaMiaomiao Zhang0Jinlong Huang1Xiaochun Zheng2Ping Huang3Xiuli Yang4School of Pharmacy, Hangzhou Normal UniversitySchool of Pharmacy, Hangzhou Normal UniversityCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeSchool of Pharmacy, Hangzhou Normal UniversityAbstract A subgroup analysis of a randomized study demonstrated that patients with advanced or metastatic liposarcoma treated with eribulin had longer overall survival and progression-free survival compared to those treated with dacarbazine, suggesting eribulin as a therapeutic option for advanced liposarcoma. Therefore, this study aims to evaluate the cost-effectiveness of eribulin versus dacarbazine in the treatment of advanced liposarcoma. We established a 10-year Markov model to compare the cost-effectiveness of eribulin and dacarbazine regimens. Clinical data were sourced from a subgroup analysis of a multicenter, randomized, open-label phase 3 trials. Quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were computed. The total cost of the dacarbazine scheme was $10,895.558, with a QALY of 0.533. In contrast, the total cost of the eribulin scheme was $16,961.891, with a QALY of 0.698. The ICER between the eribulin and dacarbazine schemes was $36,736.467, which is below the willingness-to-pay (WTP) threshold in China ($37,877.469). From the perspective of the Chinese healthcare system, eribulin is cost-effective compared to dacarbazine at the WTP threshold.https://doi.org/10.1038/s41598-024-84247-wCost-effectivenessAdvanced liposarcomaEribulinDacarbazine |
| spellingShingle | Miaomiao Zhang Jinlong Huang Xiaochun Zheng Ping Huang Xiuli Yang Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma Scientific Reports Cost-effectiveness Advanced liposarcoma Eribulin Dacarbazine |
| title | Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma |
| title_full | Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma |
| title_fullStr | Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma |
| title_full_unstemmed | Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma |
| title_short | Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma |
| title_sort | cost effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma |
| topic | Cost-effectiveness Advanced liposarcoma Eribulin Dacarbazine |
| url | https://doi.org/10.1038/s41598-024-84247-w |
| work_keys_str_mv | AT miaomiaozhang costeffectivenessanalysisoferibulinversusdacarbazineinpatientswithadvancedliposarcoma AT jinlonghuang costeffectivenessanalysisoferibulinversusdacarbazineinpatientswithadvancedliposarcoma AT xiaochunzheng costeffectivenessanalysisoferibulinversusdacarbazineinpatientswithadvancedliposarcoma AT pinghuang costeffectivenessanalysisoferibulinversusdacarbazineinpatientswithadvancedliposarcoma AT xiuliyang costeffectivenessanalysisoferibulinversusdacarbazineinpatientswithadvancedliposarcoma |